The potential for alirocumab to reduce cardiovascular events will be investigated in the large, phase III ODYSSEY Outcomes study. This trial is currently recruiting and aims to accrue around 18,000 high-risk patients including those with diabetes. The study is projected to complete by the end of 2017.
Conference Coverage
EASD: Alirocumab lipid-lowering benefits extend to patients with high-risk diabetes
Publish date: October 1, 2015
AT EASD 2015